Pfizer’s 2025 Priorities: A Roadmap to Innovation and Excellence

2024 was a year of execution for Pfizer. The company created innovative ways to reach patients, delivered on financial commitments, successfully completed the Seagen integration, and shared exciting scientific results.

During a recent fire-side chat at the 43rd Annual J.P. Morgan Annual Healthcare Conference, Pfizer’s CEO, Albert Bourla, reflected on this past year and laid out the company’s priorities for 2025 designed to enhance shareholder value. As we embark on this year, Investor Insights is excited to share additional insight on the company’s 2025 key priorities, as outlined below.

Directing R&D investments to the most impactful opportunities is Pfizer’s top focus for 2025.

• Among a series of potential R&D program advances in 2025, Pfizer expects 13 Phase 3 program starts, 8 late-stage readouts and 4 regulatory decisions, among which includes several potential mega-blockbuster treatments in oncology, vaccines and obesity.
• Under new R&D leadership, Chris Boshoff, Chief Scientific Officer and President, Research & Development oversees all functions of R&D across all therapeutic areas. His focus is to propel Pfizer’s R&D engine forward and transform it into a world-leading organization with a more focused strategy, driving the delivery of additional impactful breakthrough medicines with blockbuster potential.
• Alongside Dr. Boshoff, Andrew Baum, Pfizer’s Chief Strategy and Innovation Officer, is responsible for leading a committee to ensure Pfizer focuses its R&D investments on the most impactful opportunities.

In 2025, Pfizer will continue working towards expanded margins through improving costs and driving efficiencies.

• Simplifying operations to reduce cost and complexities remains a focus. Pfizer will continue to leverage AI and emerging technologies to help drive improvements.
• As previously announced in the second quarter of 2024, Pfizer launched a multi-year, multi-phase Manufacturing Optimization Program. Phase 1 is on track to deliver initial savings in 2025 and is expected to deliver savings of approximately $1.5 billion by the end of 2027. The company also anticipates an additional $500 million in net cost savings from its ongoing Cost Realignment Program.

Concentrating resources to accelerate growth potential among priority products and geographies is another key priority this year.

• Focus is on achieving commercial excellence in Oncology, Vaccines, Cardiovascular, Migraine, and Inflammation and Immunology.
• Additionally, Pfizer will work to expand and sustain its performance among core brands and defend against competitive entrants.

Improving free cash flow to continue driving a balanced capital allocation strategy is a priority.

• Pfizer is confident it will continue to deliver on its financial commitments and believes it is well positioned to create sustained, long-term shareholder value.
• Will also continue to advance its capital allocation strategy focused on three priorities: growing and maintaining Pfizer’s dividend, de-levering and reinvesting for the future.

2025 is a year of pipeline execution. Guided by these four priorities, we believe the company is in a strong position for 2025 and beyond to enhance shareholder value.